A simple HPTLC method having high accuracy, precision and reproducibility was developed for the routine estimation of moxifloxacin hydrochloride tablets validated according to International Conference on Harmonization (ICH) guidelines. Moxifloxacin hydrochloride was estimated at 292 nm by densitometry using Silica gel 60 F 254 as stationary phase and a premix of methylene chloride: methanol: strong ammonia solution and acetonitrile (10:10:5:10) as mobile phase. The method was found linear in a range of 9 nanograms to 54 nanograms. The correlation coefficient in between the responses observed and respective drug amounts applied was found above 0.99. The regression equation generated was-Area under the curve = 65.57  (Amount applied in nanograms) + 163.
INTRODUCTION
Moxifloxacin hydrochloride, a fluoroquinolone, is slightly yellow crystalline mono-hydrochloride salt of 1-Cyclopropyl-6-fluoro-1, 4-dihydro-8-methoxy-7-[(4aS, 7aS)-octahydro-6H-pyrrolo [3, 4-b] pyridin-6-yl]-4-oxo-3-quinoline carboxylic acid. It has been found to be effective in acute bacterial sinusitis (1) , acute bacterial exacerbation of chronic bronchitis (2) , community acquired pneumonia (3), and skin and skin structure infections (4) . Commercially, it is available as ophthalmic solutions, oral tablets and I.V. infusions in plastic containers. Various methods reported for its estimation are based on microbiological assays (5) , capillary electrophoresis (6) , voltametric determination (7) , liquid chromatography with UV detection [5] , atomic absorption spectrometry (8) and electrospray-ionization tandem mass spectrometric detection (9) .
For a cheaper and less time consuming routine analysis of Moxifloxacin Hydrochloride in bulk and formulations, the above-stated methods may be more tedious, time consuming and expertise-requiring. Hence, a simple and validated HPTLC method for the estimation of the drug in marketed tablets can be of much significance. 
EXPERIMENTAL

Thin Layer Chromatography (TLC) Development
A premix of methylene chloride: methanol: strong ammonia solution and acetonitrile in a ratio of 10:10:5:10; respectively was optimized for TLC plate development. A run distance was kept about 70 mm and 10 ml of the mobile phase was used for single development. The R f value of Moxifloxacin peak was observed about 0.51. The dosing speed of nitrogen applicator was kept at 150 nl sec -1 with a predosage volume of 0.2 µl. Samples were applied as bands of 6 mm width with the gaps of 10 mm in between. Developed plates were dried at 40 0 C for 5 min. Detection was done at 292 nm using deuterium lamp in absorption-reemission mode. The slit dimension of detection was kept 6.00 mm x 0.45 mm, scanning speed at 20 mm sec -1 and data resolution 100 µm per step.
The various statistical reports were generated according to the standard formulae and parameters were validated as per ICH [10] guidelines.
Specificity and Selectivity
Absence of any secondary spot having spectra different from Moxifloxacin Hydrochloride, in the typical constituted placebo chromatogram of the tablet preparation, which may interfere with Moxifloxacin peak, indicate the specificity of the analytical method
Calibration standards, Linearity and Range
Moxifloxacin Hydrochloride solution (4.5 g ml -1 ) was prepared in methanol and its 2, 4, 6, 8, 10 and 12 l volumes were applied on the HPTLC plate as separate spots. The plate was developed, dried and analyzed at 292 nm by densitometry. The calibration data was generated (Table 1 ) and regression analysis ( Table 2) Moxifloxacin Hydrochloride solution (4.5 g ml -1 ) was prepared in methanol and its 2, 4, 6, 8, 10 and 12 l volumes were applied on the HPTLC plate as separate spots. The plate was developed, dried and analyzed at 292 nm by densitometry. The calibration data was generated (Table 1 ) and regression analysis (Table 2 ) was performed. 
REPORTS:
1. Equation of the standard curve: y = 65.57 x +163 2.
Regression coefficient of the standard curve: 0.9908 3.
Correlation coefficient of the standard curve: 0.9954 4.
Linearity range: 9 -54 ng 
Precision and Formulation Analysis
Precision was demonstrated by analyzing the tablet preparations in six replicates. Three different Moxifloxacin Hydrochloride tablet samples-Tablet A, Tablet B and Tablet C were prepared by sonicating the tablets in methanol. % Assay calculations (as Moxifloxacin hydrochloride) were based on the calibration curve. % Relative standard deviation of the % w/w assay values were reported (Table  3) . 
Accuracy
Pre analyzed tablet sample preparations were spiked with Moxifloxacin Hydrochloride at three different levels (29.5 ng, 34.4 ng and 44.0 ng) and were analyzed in six replicates. Accuracy was reported as % recovery (Table 4) based on actual and estimated concentrations. 
Ruggedness
Ruggedness of the proposed method was determined by changing the duration of the chamber saturation i.e. 30  10 min. % Assay was reported (Table 5 ). 
RESULTS AND DISCUSSION
The proposed analytical method for assay determination of Moxifloxacin hydrochloride in tablets was found suitable and applicable to different commercially available formulations in market. The method was found linear in a range of ~ 9 to 54 ng with a good correlation of 0.99. This indicates a wide working range of the analytical method. A lower % RSD (below 2 %) of % assay values, observed during replicate analysis of different tablets as part of precision, indicate the suitability of the method.
Additionally, a lower % RSD of the % assay value justifies a high reproducibility of the analytical method. A % recovery ranging within 98-102 % demonstrated good accuracy of the analytical method. This satisfactory accuracy also rejects the chances of placebo interferences. Additionally, the method was found rugged for chamber saturation time. Chamber saturation time may vary 30 ± few minutes in real experimental conditions. Therefore, ruggedness to chamber saturation time is advantageous for TLC plate development. The proposed method can be further extended for the assay of Moxifloxacin hydrochloride in other formulations like parenteral preparations or ophthalmic solutions. 
